Physician profile
Rayees Nizam
NPI 1154375087
$11,925.44
in general payments reported to CMS, 2019-2025
35 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $1,164 · 2021: $1,462 · 2022: $1,943 · 2023: $1,984 · 2024: $1,870 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,029 · Education: $16.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,029.04 |
| Education | $16.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,027.42 | 2019-2025 | |
| Janssen Biotech, INC. | $1,624.49 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,291.32 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,197.90 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $991.75 | 2019-2025 | |
| Celgene Corporation | $371.43 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $363.78 | 2019-2025 | Dificid, Bridion |
| Regeneron Healthcare Solutions, INC. | $354.70 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $345.29 | 2019-2025 | |
| Braintree Laboratories, INC. | $333.63 | 2019-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $292.53 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $246.74 | 2022-2025 | |
| Qol Medical, LLC | $219.79 | 2019-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $180.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $167.67 | 2020-2025 | Rebyota, Clenpiq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $116.84 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $107.14 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $70.28 | 2025 | Vowst, Zenpep |
| Nestle Healthcare Nutrition INC. | $67.18 | 2021-2022 | |
| Exact Sciences Corporation | $66.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Fresenius Kabi USA, LLC | $61.35 | 2023 | Idacio |
| Ardelyx, INC. | $50.40 | 2022-2025 | Ibsrela |
| Ucb, INC. | $48.16 | 2019 | |
| Redhill Biopharma INC. | $46.26 | 2020 | |
| Ironwood Pharmaceuticals, INC | $37.67 | 2019-2022 | |
| Celltrion USA INC. | $34.78 | 2023-2025 | Vegzelma, Yuflyma |
| Amgen INC. | $29.55 | 2023 | Amjevita |
| Alfasigma USA, INC. | $29.50 | 2020 | |
| Allergan, INC. | $28.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.35 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $23.49 | 2025 | Iqirvo |
| Fujifilm Healthcare Americas Corporation | $22.52 | 2022 | |
| Vivus LLC | $19.91 | 2022 | |
| Organon LLC | $17.39 | 2023 | |
| Shire North American Group INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayees Nizam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.